Literature DB >> 24002502

Active surveillance is the preferred approach to clinical stage I testicular cancer.

Craig R Nichols1, Bruce Roth, Peter Albers, Lawrence H Einhorn, Richard Foster, Siamak Daneshmand, Michael Jewett, Padraig Warde, Christopher J Sweeney, Clair Beard, Tom Powles, Scott Tyldesley, Alan So, Christopher Porter, Semra Olgac, Karim Fizazi, Brandon Hayes-Lattin, Peter Grimison, Guy Toner, Richard Cathomas, Carsten Bokemeyer, Christian Kollmannsberger.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24002502     DOI： 10.1200/JCO.2012.47.6010

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  24 in total

1.  Testicular cancer: Optimal management of stage I seminoma in 2015.

Authors:  Guy C Toner
Journal:  Nat Rev Urol       Date:  2015-04-21       Impact factor: 14.432

2.  The Sound of Silence: A Proxy for Platinum Toxicity.

Authors:  Jan Oldenburg; Jourik A Gietema
Journal:  J Clin Oncol       Date:  2016-07-05       Impact factor: 44.544

3.  Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out.

Authors:  Rune A W van de Wetering; Stefan Sleijfer; Darren R Feldman; Samuel A Funt; George J Bosl; Ronald de Wit
Journal:  J Clin Oncol       Date:  2018-02-01       Impact factor: 44.544

4.  Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.

Authors:  Mahmut Gumus; Ahmet Bilici; Hatice Odabas; Bala Basak Oven Ustaalioglu; Nurten Kandemir; Umut Demirci; Sener Cihan; Ibrahim Vedat Bayoglu; Turkan Ozturk; Esma Turkmen; Zurat Urakci; Mehmet Metin Seker; Yusuf Gunaydin; Fatih Selcukbiricik; Nedim Turan; Alper Sevinc
Journal:  World J Urol       Date:  2016-11-03       Impact factor: 4.226

5.  Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry.

Authors:  Stanley A Yap; Lindsay M Yuh; Christopher P Evans; Marc A Dall'Era; Rebecca M Wagenaar; Rosemary Cress; Primo N Lara
Journal:  World J Urol       Date:  2016-06-15       Impact factor: 4.226

Review 6.  Current management and management controversies in early- and intermediate-stage of nonseminoma germ cell tumors.

Authors:  Salim K Cheriyan; Marilin Nicholson; Ahmet M Aydin; Mounsif Azizi; Charles C Peyton; Wade J Sexton; Scott M Gilbert
Journal:  Transl Androl Urol       Date:  2020-01

7.  A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion.

Authors:  C A Lago-Hernandez; H Feldman; E O'Donnell; B A Mahal; V Perez; S Howard; M Rosenthal; S C Cheng; P L Nguyen; C Beard; A V D'Amico; C J Sweeney
Journal:  Ann Oncol       Date:  2015-04-17       Impact factor: 32.976

8.  Management of clinical stage I testicular seminoma: active surveillance versus adjuvant chemotherapy.

Authors:  M Ondrusova; D Ondrus; V Miskovska; K Kajo; K Szoldova; V Usakova; V Stastna
Journal:  Int Urol Nephrol       Date:  2015-05-16       Impact factor: 2.370

Review 9.  Management of stage I testicular germ cell tumours.

Authors:  Michal Chovanec; Nasser Hanna; K Clint Cary; Lawrence Einhorn; Costantine Albany
Journal:  Nat Rev Urol       Date:  2016-09-13       Impact factor: 14.432

Review 10.  Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration.

Authors:  Thomas A Olson; Matthew J Murray; Carlos Rodriguez-Galindo; James C Nicholson; Deborah F Billmire; Mark D Krailo; Ha M Dang; James F Amatruda; Claire M Thornton; G Suren Arul; Sara J Stoneham; Farzana Pashankar; Daniel Stark; Furqan Shaikh; David M Gershenson; Allan Covens; Jean Hurteau; Sally P Stenning; Darren R Feldman; Peter S Grimison; Robert A Huddart; Christopher Sweeney; Thomas Powles; Luiz Fernando Lopes; Simone dos Santos Agular; Girish Chinnaswamy; Sahar Khaleel; Sherif Abouelnaga; Juliet P Hale; A Lindsay Frazier
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.